Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · May 17, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a special drink made from ketones can help improve symptoms in individuals with schizophrenia or bipolar disorder. The main goal is to find out if this drink can enhance how well patients process information and think clearly. Researchers will compare the effects of the ketone drink to a similar drink made from carbohydrates, allowing them to see which one works better for the participants.
To be eligible for this trial, participants need to be at least 18 years old and experiencing their first episode of psychosis related to schizophrenia or a (hypo)manic or depressive episode related to bipolar disorder. It’s important that they are receiving standard medical care, including medications for their condition. During the study, participants will drink both types of beverages and undergo various tests to measure their thinking abilities, mood, and overall health over several days. They will also wear devices to monitor their glucose levels and gather information about their diet and energy use. This trial is currently recruiting, and it aims to provide valuable insights into new ways to support individuals with these mental health conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with a first-episode psychosis (underlying schizophrenia-spectrum disorder), or patients with a (hypo)manic or depressive episode (underlying bipolar disorder)
- • Age \>= 18 years old
- • Receiving standard care (including antipsychotic and mood stabilizing medication)
- * Mentally competent to give informed consent:
- Exclusion Criteria:
- • Substance use as cause of psychosis or (hypo)mania
- • Substance use (other than nicotine) in the week prior to study onset
- • Intellectual disability
- • Diabetes mellitus (type 1 or type 2)
- • Metabolic disease impacting ketone metabolism (NB: these are rare disorders diagnosed during childhood)
- • Liver disease
- • Kidney disease
- • Cardiovascular disease
- • Pregnancy
- • Breastfeeding
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, Noord Holland, Netherlands
Patients applied
Trial Officials
Karin Huizer, MD/PhD
Principal Investigator
Parnassia Groep
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported